-
Study aim
-
Comparison of Pregabalin and Cinnarizine on prophylactic treatment of children with migraine
-
Design
-
A clinical trial with parallel groups, double-blinded, randomized (permuted block randomization), phase 3 on 74 children with migrane, using www.sealedenvelope.com for randomization.
-
Settings and conduct
-
This study is conducted in Rasool Akram Hospital. Children with migraine are randomly assigned into two groups. In the first group, children take Pregabalin oral capsule. In the second group, children take Cinnarizine tablet. In this study, participants and physicians did not know the type of medication they received.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: children aged 6 to 17 years with migraine prophylaxis, Migraine diagnosis based on the criteria of the International Headache Society, which includes cases of migraine without aura (5 attacks), migraine with aura (2 attacks), and each attack lasts 1 to 72 hours, and it is pulsating and severe, and accompanied by symptoms With nausea or vomiting, photophobia, phonophobia, Not taking pregabalin and cinnarizine in the past
Exclusion Criteria:Drug Intolerance (symptoms such as diarrhea, nausea and vomiting),anaphylaxis, severe dizziness, excessive sleepiness
-
Intervention groups
-
In the first intervention group, a Pregabalin oral capsule 50 mg or 75 (manufactured by Actoverco, Iran)mg was prescribed for weight of less than 30 kg and more than 30kg respectively, one time a day for 3 month. The second intervention group, a Pregabalin oral capsule 25 mg or 50 (manufactured by Amin pharmaceutical, Iran)mg was prescribed for weight of less than 30 kg and more than 30kg respectively, one time a day for 3 month.
-
Main outcome variables
-
Frequency of migraine headaches